Equities

Enorama Pharma AB

ERMA:STO

Enorama Pharma AB

Actions
  • Price (SEK)2.33
  • Today's Change0.00 / 0.00%
  • Shares traded9.42k
  • 1 Year change-17.62%
  • Beta1.1126
Data delayed at least 15 minutes, as of May 31 2024 17:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Enorama Pharma AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company is mainly focused on the development of medical chewing gum that contains drugs. The Company's product Nicotine gum is a chewing gum contained drugs that help to overcome nicotine addiction. In addition, the medical chewing gum applications include pain management, allergy, cough and cold, among others. The Company distributes its products in Europe through pharmacy chains and grocery stores.

  • Revenue in SEK (TTM)670.00k
  • Net income in SEK-42.47m
  • Incorporated2006
  • Employees5.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bio-Works Technologies AB43.90m-56.82m106.03m38.00--2.41--2.42-1.58-1.581.221.130.5711.825.831,155,158.00-73.91-49.14-101.72-57.9061.1069.88-129.44-168.302.79--0.00--6.2346.24-26.41--1.95--
Alzinova AB270.00k-16.48m107.35m5.00--0.6268--397.58-0.3385-0.33850.00552.070.0023--0.367154,000.00-14.04-10.77-14.91-11.277,360.92---6,103.69-18,447.90----0.007-------25.92--15.81--
NextCell Pharma AB12.45m-39.37m109.38m----1.18--8.79-0.9046-0.90460.2861.280.140614.067.20---44.45-34.92-50.09-37.0612.04-68.21-316.25-538.604.36--0.00--80.9672.85-15.21------
Odi Pharma AB (publ)818.38k-3.97m110.35m----54.19--134.83-0.2608-0.26080.05380.13380.10841.226.98---52.58---95.24---53.07---484.96--1.32-14.100.00---55.44--4.67------
Bioextrax AB publ1.63m-22.16m110.60m----6.04--67.93-0.8034-0.80340.05880.53150.0686--4.96---93.29-86.39-102.02-110.843.62---1,360.93-2,119.90----0.00--420.5124.40-15.21--56.86--
New Nordic Healthbrands AB537.81m-10.17m113.37m70.00--1.09--0.2108-1.64-1.6486.8116.862.161.844.967,367,219.00-4.095.36-9.1610.5565.3267.30-1.892.380.8584-4.440.282147.969.516.28-119.41--28.36--
Coegin Pharma AB0.00-27.98m113.92m0.00--8.75-----2.65-2.650.000.64030.00-------125.24-122.02-201.53-154.70-------28,466.75---170.650.00------20.60------
Isofol Medical AB (publ)0.00-31.16m115.81m4.00--1.03-----0.1964-0.19640.000.69930.00----0.00-20.49-66.73-24.10-88.27-------1,023.62----0.00---94.37--76.80------
StenoCare A/S6.28m-25.74m124.99m9.00--3.64--19.89-1.13-1.130.26741.220.1285--2.94---52.62-28.16-70.34-35.47-----409.55-371.061.04-5.560.2362---16.30---7.77------
Enorama Pharma AB670.00k-42.47m128.73m5.00--5.46--192.13-1.03-1.030.01630.42710.01840.75830.6384134,000.00-116.48-73.56-184.45-104.85-635.0743.36-6,338.66-557.420.4626-605.700.02---80.17-23.71-6.15------
Circa Group AS18.73m-71.89m136.39m17.00--0.3977--7.28-0.6578-0.65780.16892.800.04035.460.91391,098,678.00-15.46---19.96--75.64---383.72--0.7097--0.00--41.73---0.0491------
Toleranzia AB0.00-6.30m137.95m7.00--0.9032-----0.0405-0.04050.000.7750.00----0.00-4.50-7.45-4.65-7.78------------0.00------11.79--63.90--
PMD Device Solutions AB28.62m-36.18m139.69m1.00------4.88-16.69-16.696.34-4.790.9465--57.42---119.63------58.18---126.39--0.0505-3.00----------------
Bactiquant A/S18.84m-20.07m143.92m----6.52--7.64-0.6358-0.63580.59710.61330.50553.672.83---53.83-41.26-62.59-47.16-6.1412.89-106.51-71.775.43-8.540.0431---0.689--7.62------
Lipum AB (publ)0.00-37.18m145.31m5.00--14.50-----4.38-4.380.000.47260.00----0.00-159.35-127.85-206.31-184.50-------293,228.70----0.2781------2.38------
Xintela AB377.00k-49.24m152.52m--------404.57-0.1217-0.12170.0008-0.01360.0193--0.0447---252.59-181.06---391.61100.00---13,061.54-235,894.00---49.47-------45.5418.32---61.47--
Data as of May 31 2024. Currency figures normalised to Enorama Pharma AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.